← Back to Search

Antiviral

RV521 Capsules for Stem Cell Transplant Complications (REVIRAL2 Trial)

Phase 2
Waitlist Available
Research Sponsored by ReViral Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has undergone autologous or allogeneic HCT using any conditioning regimen within 1 year of randomization. Subjects who have undergone HCT more than 1 year before Randomization are eligible if all other inclusion/
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up collected at visit 2/day 1 (pre-dose), visit 4/day 3, visit 6/day 14 and visit 8/day 28
Awards & highlights

REVIRAL2 Trial Summary

This trial is testing a new RSV drug for people who are at high risk for complications and have had a bone marrow transplant.

Eligible Conditions
  • Stem Cell Transplant Complications
  • Respiratory Syncytial Virus
  • Lower Respiratory Tract Infection

REVIRAL2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

REVIRAL2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~collected at visit 2/day 1 (pre-dose), visit 4/day 3, visit 6/day 14 and visit 8/day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and collected at visit 2/day 1 (pre-dose), visit 4/day 3, visit 6/day 14 and visit 8/day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in RSV nasal viral load (via RT-qPCR)
Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study
Secondary outcome measures
Evaluate safety and tolerability of RV521 by assessing changes from baseline in body temperature (vital sign parameters)
Evaluate safety and tolerability of RV521 by assessing changes from baseline in pulse/heart rate (vital sign parameters)
Evaluate safety and tolerability of RV521 by assessing changes from baseline in respiration rate (vital sign parameters)
+21 more

REVIRAL2 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RV521 CapsulesExperimental Treatment1 Intervention
RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
Group II: RV521 Placebo CapsulesPlacebo Group1 Intervention
RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.

Find a Location

Who is running the clinical trial?

ReViral LtdLead Sponsor
4 Previous Clinical Trials
208 Total Patients Enrolled
PfizerLead Sponsor
4,567 Previous Clinical Trials
10,911,873 Total Patients Enrolled
Seth Hetherington, MDStudy DirectorReViral Ltd
1 Previous Clinical Trials
51 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV
2020. "Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04267822.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top